Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid ...

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial ...

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...

Arnab Basu, MD, MPH, FACP, explains why sensitivity might be higher in urothelial cancer vs other genitourinary cancers.

Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with ...

During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...